ハンチントン病治療市場規模、シェア、動向分析レポート：治療別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

ハンチントン病治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のハンチントン病治療市場規模は2025年から2030年にかけて23.8%のCAGRを記録し、2030年までに18億7,120万米ドルに達する見込みです。

この成長は、新製品開発のための高い研究開発投資、共同研究、欧米諸国における高HD負担によるものです。ハンチントン病はまれな遺伝性神経変性疾患であり、数世代にわたって罹患します。30歳から50歳の間に発症し、仕事や家族の世話をする能力が損なわれ、最終的には日常の仕事をこなすことができなくなります。

有病率は地域によって10倍以上の差があり、これは症例の把握や診断基準のばらつきに関係していると考えられます。有病率は地理的な場所によって10倍以上の差があり、これは症例確認や診断基準のばらつきに関係している可能性があります。その結果、一般集団における反復性肥大の有病率は予想以上に高い可能性があります。アジアでは一貫して有病率が低く、北米、オーストラリアでは有病率が高いです。

ニューロクライン・バイオサイエンシズ社やアゼバン・ファーマシューティカルズ社などの主な企業は、HDの対症療法の研究開発に注力しています。Azevan Pharmaceuticals社は、ハンチントン病の精神神経症状を治療する実験薬としてSRX246を開発しています。SRX246は、脳内のバソプレシン1a（V1a）受容体を阻害することで効果を発揮する薬剤です。神経系では、V1a受容体は主要なバソプレシン受容体です。SRX246は、V1a受容体を阻害することにより、バソプレシンが受容体に結合するのを制限し、ハンチントン病患者に見られる過敏で攻撃的な行動を引き起こします。

しかし、現在承認されている薬剤は対症療法や緩和ケアであり、病気の根本的な原因を治療するものではないです。薬物療法は症状の重篤度を減少させることはできるが、傾眠、歩行障害、嚥下障害、無気力などの副作用を伴うことが多く、患者のQOLに深刻な影響を及ぼす可能性があります。この疾患の治療法が確立されていないことを考えると、これらの患者において健康関連QOL（HRQOL）がどのような影響を受けるかを評価することは極めて重要です。病気の初期から中期のHD患者には、認知機能の評価やカウンセリングなど、集学的な医療サービスが必要です。

HDに対する薬剤開発は、いくつかの治療法が有効性を実証できなかったり、重大な毒性を伴うなど、大きな障害に直面してきました。2020年9月、Vaccinex Inc.のペピネマブの第II相試験は、初期の顕性HD患者および前駆期HD患者を対象として、事前に指定された共同主要評価項目を満たすことができませんでした。SIGNAL試験において、2つの共同主要評価項目（ハンチントン病認知機能評価バッテリーとCGIC（Clinical Global Impression of Change）の2つの認知機能評価項目）は、早期症状集団において統計学的有意性を達成しなませんでした。

ハンチントン病治療市場レポートハイライト

• 対症療法分野は、製品の入手可能性と特許保護により、2024年に最大の売上シェアを占めました。疾患修飾療法は、SAGE-718やCellavita-HDの参入により、予測期間中に最も急成長する分野と予想されます。
• 各社は現在、変異タンパク質を標的とするのではなく、脳に直接注射して変異HTTタンパク質の形成を直接阻害する治療法の開発に注力しています。
• 開発初期段階にある新規ターゲットを持つ薬剤としては、Cellavita社とAzidus Brazil社のCellavita HD（幹細胞治療）、Sangamo Therapeutics社のmHTT ZFP（ジンクフィンガープロテイン）、UniQure社のAMT-130（遺伝子治療）などがあります。
• 北米は2024年に最も高い収益シェアを占め、米国とカナダでは償還施設が充実していることとHDの負担が大きいことから、予測期間中も市場を独占するとみられます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ハンチントン病治療市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析
  • パイプライン分析

第4章 ハンチントン病治療市場：治療推定・動向分析

• 世界のハンチントン病治療市場：治療ダッシュボード
• 世界のハンチントン病治療市場：治療変動分析
• ハンチントン病治療市場（治療、収益別）
• 治療
• 疾患修飾療法

第5章 ハンチントン病治療市場：流通チャネルの推定・動向分析

• ハンチントン病治療の世界市場：流通チャネルダッシュボード
• ハンチントン病治療の世界市場：流通チャネル変動分析
• ハンチントン病治療市場（流通チャネル別、収益別）
• 病院薬局
• 小売薬局
• オンライン薬局

第6章 ハンチントン病治療市場：治療、用途、流通チャネル別の地域推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • Key customers
  • Key company market share analysis, 2024年
  • H. Lundbeck A/S.
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Companies Inc.
  • Hetero
  • Lupin
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • uniQure NV.
  • Latus Bio

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 3 North America Huntington's Disease Treatment Market, by Distribution Channel 2018 - 2030 (USD Million)
• Table 4 U.S. Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 5 U.S. Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 6 Canada Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 7 Canada Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 8 Mexico Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 9 Mexico Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 10 Europe Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 11 Europe Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 12 Germany Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 13 Germany Huntington's Disease Treatment Market, by Application, 2018 - 2030 (USD Million)
• Table 14 UK Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 15 UK Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 France Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 17 France Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 18 Italy Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 19 Italy Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 20 Spain Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 21 Spain Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 Asia Pacific Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 23 Asia Pacific Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 24 China Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 25 China Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 Japan Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 27 Japan Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 India Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 29 India Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 30 South Korea Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 31 South Korea Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Latin America Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 33 Latin America Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Brazil Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 35 Brazil Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 36 MEA Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 37 MEA Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 South Africa Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 39 South Africa Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 40 Saudi Arabia Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 41 Saudi Arabia Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 42 UAE Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 43 UAE Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Kuwait Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 45 Kuwait Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Huntington's Disease Treatment Market Segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 QFD modelling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Treatment and Distribution Channel segment snapshot
• Fig. 10 Distribution Channel segment snapshot
• Fig. 11 Competitive landscape snapshot
• Fig. 12 Pharmaceutical market (USD Billion)
• Fig. 13 Market dynamics
• Fig. 14 Porter's five forces analysis
• Fig. 15 PESTLE analysis
• Fig. 16 Huntington's Disease Treatment market: Treatment outlook and key takeaways
• Fig. 17 Huntington's Disease Treatment market: Treatment movement analysis
• Fig. 18 Symptomatic Treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Disease-modifying Therapies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Huntington's Disease Treatment market: Distribution Channel outlook and key takeaways
• Fig. 21 Huntington's Disease Treatment Market: Distribution Channel movement analysis
• Fig. 22 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Retail Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Huntington's Disease Treatment market revenue, by region, 2024 & 2030, (USD million)
• Fig. 26 Regional marketplace: Key takeaways
• Fig. 27 Regional marketplace: Key takeaways
• Fig. 28 North America Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Key country dynamics
• Fig. 30 Target disease prevalence
• Fig. 31 U.S. Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Key country dynamics
• Fig. 33 Target disease prevalence
• Fig. 34 Canada Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Mexico Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Key country dynamics
• Fig. 37 Target disease prevalence
• Fig. 38 Europe Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Key country dynamics
• Fig. 40 Target disease prevalence
• Fig. 41 UK Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Key country dynamics
• Fig. 43 Target disease prevalence
• Fig. 44 Germany Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Key country dynamics
• Fig. 46 Target disease prevalence
• Fig. 47 France Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Key country dynamics
• Fig. 49 Target disease prevalence
• Fig. 50 Spain Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Key country dynamics
• Fig. 52 Target disease prevalence
• Fig. 53 Italy Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Key country dynamics
• Fig. 55 Target disease prevalence
• Fig. 56 Denmark Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Key country dynamics
• Fig. 58 Target disease prevalence
• Fig. 59 Sweden Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Key country dynamics
• Fig. 61 Target disease prevalence
• Fig. 62 Norway Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Asia Pacific Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Key country dynamics
• Fig. 65 Target disease prevalence
• Fig. 66 Japan Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Key country dynamics
• Fig. 68 Target disease prevalence
• Fig. 69 China Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Key country dynamics
• Fig. 71 Target disease prevalence
• Fig. 72 India Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Key country dynamics
• Fig. 74 Target disease prevalence
• Fig. 75 Australia Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Key country dynamics
• Fig. 77 Thailand Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Key country dynamics
• Fig. 79 South Korea Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Latin America Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Key country dynamics
• Fig. 82 Target disease prevalence
• Fig. 83 Brazil Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Key country dynamics
• Fig. 85 Target disease prevalence
• Fig. 86 Argentina Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 MEA Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Key country dynamics
• Fig. 89 Target disease prevalence
• Fig. 90 South Africa Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Key country dynamics
• Fig. 92 Target disease prevalence
• Fig. 93 Saudi Arabia Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Key country dynamics
• Fig. 95 Target disease prevalence
• Fig. 96 UAE Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 97 Key country dynamics
• Fig. 98 Target disease prevalence
• Fig. 99 Kuwait Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)

Huntington's Disease Treatment Market Growth & Trends:

The global huntington's disease treatment market size is expected to reach USD 1,871.2 million by 2030, registering a CAGR of 23.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.

The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. As a result, the prevalence of enlarged repetitions in the general population may be greater than expected. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence.

The key players, such as Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are focusing on research and development of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an experimental drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in the brain. In the neurological system, V1a receptor is the major vasopressin receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin from attaching to the receptor, and generating irritable and aggressive behavior, which is seen in Huntington's disease patients.

However, currently approved drugs provide symptomatic and palliative care and do not target the underlying cause of the disease. While medications can decrease the severity of symptoms, they are often associated with adverse effects such as somnolence, gait issues, dysphagia, and apathy, which can have serious impacts on a patient's quality of life. Given the lack of a cure for the disease, it is critical to evaluate how Health-related Quality of Life (HRQOL) is affected in these patients. HD patients in early to middle stages of the disease need coordinated multidisciplinary healthcare services, including assessment of cognitive function and counseling.

Drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. Vaccinex Inc.'s phase II trial of Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with early manifest and prodromal HD, in September 2020. The two co-primary endpoints-a family of two cognitive evaluations from the Huntington's disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC)-did not attain statistical significance in the early manifestation population in the SIGNAL study.

Huntington's Disease Treatment Market Report Highlights:

• The symptomatic treatment segment accounted for the largest revenue share in 2024 owing to the product availability and patent protection. Disease-modifying therapies is anticipated to be the fastest-growing segment over the forecast years due to the entry of SAGE-718, and Cellavita-HD
• Companies are now focusing on the development of treatments that can be injected directly into the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein
• Drugs with novel targets in early-phase development include Cellavita and Azidus Brazil's Cellavita HD (stem cell therapy), Sangamo Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure's AMT-130 (gene therapy)
• North America held the highest revenue share in 2024 and is expected to dominate the market over the forecast period due to better reimbursement facilities and the high burden of HD in the U.S. and Canada

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. Distribution Channel
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment and Distribution Channel Outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising anti-aging burden
    • 3.2.1.2. Advancements in drug development
    • 3.2.1.3. Growing awareness about anti-aging treatment
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of development
    • 3.2.2.2. Regulatory challenges for new drug approvals
• 3.3. Huntington's Disease Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Pipeline Analysis
    • 3.3.4.1. Phase 1
    • 3.3.4.2. Phase 2
    • 3.3.4.3. Phase 2

Chapter 4. Huntington's Disease Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Global Huntington's Disease Treatment Market: Treatment Dashboard
• 4.2. Global Huntington's Disease Treatment Market: Treatment Movement Analysis
• 4.3. Global Huntington's Disease Treatment Market by Treatment, Revenue
• 4.4. Symptomatic Treatment
  • 4.4.1. Symptomatic Treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Disease-modifying Therapies
  • 4.5.1. Disease-modifying Therapies market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Huntington's Disease Treatment Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Global Huntington's Disease Treatment Market: Distribution Channel Dashboard
• 5.2. Global Huntington's Disease Treatment Market: Distribution Channel Movement Analysis
• 5.3. Global Huntington's Disease Treatment Market by Distribution Channel, Revenue
• 5.4. Hospital Pharmacy
  • 5.4.1. Hospital Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Retail Pharmacy
  • 5.5.1. Retail Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Online Pharmacy
  • 5.6.1. Online Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Huntington's Disease Treatment Market: Regional Estimates & Trend Analysis by Treatment, Application, and Distribution Channel

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. H. Lundbeck A/S.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Teva Pharmaceutical Industries Ltd.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Treatment benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Bausch Health Companies Inc.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Hetero
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Lupin
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Hikma Pharmaceuticals PLC
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Dr. Reddy's Laboratories Ltd.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Sun Pharmaceutical Industries Ltd.
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Novartis AG
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. uniQure NV.
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Latus Bio
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives